Advice
Following a full submission Gemcitabine (Gemzar) in combination with paclitaxel is not recommended for use within NHS Scotland for the treatment of patients with metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy.
Gemcitabine in combination with paclitaxel has improved outcomes, compared to paclitaxel monotherapy, in those previously treated with an anthracycline. However the economic case has not been demonstrated.
The licence holder has indicated their decision to resubmit.
Download detailed advice46KB (PDF)
Medicine details
- Medicine name:
- Gemcitabine/paclitaxel (Gemzar®)
- SMC ID:
- 154/05
- Indication:
- In combination with paclitaxel for the treatment of metastatic breast cancer
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 07 March 2005